| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Alto Neuroscience | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $253.17M | Series C | 11/21/2023 | $50.31M | $235.65M | $4.71 | InVivium Capital, Franklin Templeton, Point72, Eli Lilly and Company, Alexandria Venture Investments, Alpha Wave Ventures, Lightswitch Capital, Alkeon Capital, WhatIf Ventures, Windham Venture Partners | ||||
 | ArriVent Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $260M | Series B | 12/16/2022 | $110M | $375.08M | $1.05 | Undisclosed Investors | ||||
 | Bicara Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $710.05M | Series C | 12/12/2023 | $165M | $495.55M | $1.38 | Braidwell LP, TPG, The Rise Fund, Deerfield Management, Fairmount, Aisling Capital, Red Tree Venture Capital, RA Capital Management, F-Prime Capital, Eight Roads Ventures, Invus Piper Heartland Healthcare Capital, Premji Invest, Omega Funds, Bioqube Ventures, Acorn Bioventures, Janus Henderson Investors | ||||
 | Doximity | Consumer & Lifestyle Social | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $81.67M | Series C | 4/29/2014 | $53.84M | $480.12M | $2.41 | Threshold Ventures, T. Rowe Price, Morgan Stanley, Morgenthaler, Emergence Capital, InterWest Partners, Buena Vista Angels | ||||
 | Oportun | Fintech Lending | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $169.02M | Series G | 9/5/2013 | $46.78M | $223.54M | $1.14 | TPG Capital, Madrone Capital Partners, IVP, Hercules Capital, Greylock Partners, Great Oak Venture Partners | ||||
 | Rapport Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250.18M | Series B | 8/7/2023 | $150M | $409.19M | $1.68 | Cormorant Asset Management, Fidelity Management & Research Company, Goldman Sachs Asset Management, Logos Capital, Perceptive Advisors, Sofinnova Investments, Surveyor Capital, Third Rock Ventures, ARCH Venture Partners, Johnson & Johnson Innovation | ||||
 | Septerna | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $225M | Series B | 7/11/2023 | $150M | $313.42M | $1.23 | RA Capital Management, Third Rock Ventures, Samsara BioCapital, Invus, Catalio Capital Management, BVF Partners, Casdin Capital, Logos Capital, Deep Track Capital, Goldman Sachs Asset Management, Vertex Ventures HC, Mirae Asset Financial Group, Direhaus Capital Management, Woodline Partners LP, Soleus Capital | ||||
 | Contineum Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $133.61M | Series C | 2/11/2021 | $80.4M | $244.63M | $2.68 | Perceptive Advisors, Franklin Templeton, Casdin Capital, Samsara BioCapital, Suvretta Capital, Red Tree Venture Capital, Versant Ventures, Sectoral Asset Management, Cleva Pharma | ||||
 | Expensify | Enterprise Software Business Operations | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $28.21M | Series C | 1/23/2015 | $17.5M | $141M | $15.57 | OpenView Venture Partners, Redpoint Ventures, Hillsven, PJC | ||||
 | Arcellx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $235.48M | Series C | 4/13/2021 | $120M | $377.76M | $2.10 | Samsara BioCapital, CAM Capital, Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital, Suvretta, Terra Magnum Capital Partners, New Enterprise Associates, Novo Holdings, SR One, Takeda Ventures, LG Tech, Clough Capital | ||||
 | Slide Insurance | Fintech Insurance | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $200M | Series A | 11/22/2021 | $100M | $378.18M | $13.64 | Gries Investment Funds, Tampa Bay Ventures | ||||
 | Cue Health | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $179.56M | Series C-1 | 6/10/2020 | $100M | $455.86M | $3.66 | Decheng Capital, Foresite Capital, Madrone Capital Partners, Johnson & Johnson Innovation, ACME Capital | ||||
 | PubMatic | Enterprise Software Sales & Marketing / Adtech | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $65.26M | Series DP | 2/6/2014 | $14.47M | $241.43M | $4.82 | Nokia Growth Partners, August Capital, Draper Fisher Jurvetson, Helion Venture Partners, SharesPost, Nexus Venture Partners | ||||
 | IsoPlexis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $161.52M | Series D | 1/7/2021 | $92.5M | $348.21M | $76.92 | Perceptive Advisors, Ally Bridge Group, BlackRock | ||||
 | Codiak BioSciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $168.37M | Series C | 11/29/2017 | $76.37M | $404.14M | $3.78 | ARCH Venture Partners, Flagship Pioneering, Fidelity Management and Research Company, the Alaska Permanent Fund, Alexandria Venture Investments | ||||
 | Eargo | Consumer & Lifestyle Consumer Electronics | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $232.63M | Series E | 9/1/2020 | $84.14M | $241.8M | $6.78 | Gilde Healthcare, Longitude Capital, New Enterprise Associates, Charles and Helen Schwab Foundation, Nan Fung Life Sciences | ||||